2010 12th Annual Lynn Sage Breast Cancer Breakout Sessions

The following meal symposia are complimentary for participants of the Lynn Sage Breast Cancer Symposium. Session seating is limited and is on first-come, first-seated basis.

Friday, October 29, 2010
New Insights Into the Effects of Cancer Therapy On Bone Health
Time: 6:30 am
Faculty: Adam Brufsky, MD, PhD; Robert Coleman, MD
Moderator: William Gradishar, MD

Objectives
1) Discuss the critical growth factor pathways governing the formation and destruction of bone

2) Explain the impact of breast cancer therapy on bone density

3) Describe therapeutic strategies to maintain bone health

Friday, October 29, 2010
Complex Local Therapy Issues in Breast Cancer
Time: 12:15 pm
Faculty: Tari King, MD; Abram Recht, MD
Moderator: Monica Morrow, MD

Objectives
1) Discuss role of mastectomy in patients with de novo metastatic breast cancer

2) Discuss the data supporting a radiation boost for patients undergoing lumpectomy and adjuvant radiation therapy

3) Explain the issues related to what constitutes an adequate surgical margin in patients with invasive or non-invasive breast cancer

4) Explain the clinical impact of post-mastectomy radiation therapy in patients with node –negative or positive breast cancer

Saturday, October 30, 2010
Endocrine Therapy for Breast Cancer in the 21st Century
Time: 7:00 am
Faculty: Harold Harvey, MD; Vered Stearns, MD
Moderator: Virginia Kaklamani, MD, DSc

Objectives
1) Discuss the optimal use of aromatase inhibitors for adjuvant treatment of early stage breast cancer

2) Describe novel strategies to combine endocrine agents with other targeted biological agents

3) Explain emerging data regarding novel schedules for endocrine agents in patients with metastatic breast cancer

Saturday, October 30, 2010
Optimizing the Clinical Outcomes of Patients With HER2+ Breast Cancer

Time: 12:30 pm
Faculty: Stefan Gluck, MD, PhD; Deborah Toppmeyer, MD
Moderator: Mary Cianfrocca, DO

Objectives
1) Discuss evidence supporting the role of adjuvant trastuzumab in sub-centimeter tumors
 
2) Describe the controversies regarding HER2 assessment
 
3) Translate the emerging data regarding the efficacy of novel anti –HER2 agentsy.

The Following Statements Apply To Each Breakout Session:

Accreditation Statement
The Northwestern University’s Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The Northwestern University’s Feinberg School of Medicine designates each of the four breakout sessions for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.